Clinical trial

Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)

NCT05029583

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

OTHER · Unmapped registry intervention routine screening Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention physician-driven screening Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Clinical Outcomes From Enhanced SCREENing Strategies for NASH in Type 2 Diabetes (SCREEN NASH T2D)

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2021-08-11

PhaseNA

Conditions

Nonalcoholic Steatohepatitisverified · MONDO: metabolic dysfunction-associated steatohepatitis

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

Interventions

routine screeningOTHER

physician-driven screeningOTHER

Sponsors & collaborators

LMC Diabetes & Endocrinology Ltd.lead sponsor

Mapped research locations

TorontoOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05029583 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.